Quinupramine (10 mg/kg, PO, twice daily for 10 days) causes a down-regulation of serotonin S2 receptors in the frontal cortex of the rat[2].
Quinupramine-EVA matrix containing a permeation enhancer can be a good transdermal delivery system for providing sustained plasma concentrations[3].
| Animal Model: | Sprague-Dawley rats (Male, 220-270 g) |
| Dosage: | 10 mg/kg |
| Administration: | PO, twice daily for 10 days |
| Result: | Caused a down-requlation of serotonin S2 receptors in the frontal cortex of the rat, did not alter the binding populations of Q-adrenergic, muscarinic cholinergic and a2-adrenergic receptors in the rat brain. |
